|Dr. Harold H. Shlevin||Pres, CEO & Director||N/A||N/A||1950|
|Mr. Jack W. Callicutt CPA, CPA||CFO & Sec.||N/A||N/A||1967|
|Robert Tritt||Gen. Counsel||N/A||N/A||N/A|
|Dr. Eliezer Zomer||Exec. VP of Manufacturing & Product Devel.||N/A||N/A||1947|
|Dr. Pol F. Boudes||Chief Medical Officer||N/A||N/A||1957|
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 2; Compensation: 8.